Financhill
Buy
66

CAH Quote, Financials, Valuation and Earnings

Last price:
$151.95
Seasonality move :
1.22%
Day range:
$147.74 - $149.52
52-week range:
$93.17 - $154.07
Dividend yield:
1.36%
P/E ratio:
23.15x
P/S ratio:
0.16x
P/B ratio:
--
Volume:
2M
Avg. volume:
2.9M
1-year change:
52.32%
Market cap:
$35.4B
Revenue:
$226.8B
EPS (TTM):
$6.41

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CAH
Cardinal Health
$55.3B $2.15 1.46% 104.05% $155.47
BIO
Bio-Rad Laboratories
$573.2M $1.78 -3.73% -86.75% $318.67
BSX
Boston Scientific
$4.6B $0.67 18.78% 229.2% $116.20
COR
Cencora
$75.8B $4.10 8.14% 56.12% $317.09
MASI
Masimo
$367.8M $1.21 -25.72% 321.55% $182.07
MCK
McKesson
$94.3B $9.82 20.2% 18.43% $744.58
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CAH
Cardinal Health
$148.41 $155.47 $35.4B 23.15x $0.51 1.36% 0.16x
BIO
Bio-Rad Laboratories
$237.07 $318.67 $6.5B -- $0.00 0% 2.62x
BSX
Boston Scientific
$102.95 $116.20 $152.3B 75.15x $0.00 0% 8.73x
COR
Cencora
$279.15 $317.09 $54.1B 32.38x $0.55 0.76% 0.18x
MASI
Masimo
$153.15 $182.07 $8.3B 116.80x $0.00 0% 4.21x
MCK
McKesson
$682.28 $744.58 $85.3B 26.41x $0.71 0.4% 0.24x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CAH
Cardinal Health
162.31% 0.200 22.64% 0.44x
BIO
Bio-Rad Laboratories
15.25% 1.030 17.86% 4.12x
BSX
Boston Scientific
33.49% 1.029 7.48% 0.68x
COR
Cencora
88.58% 0.081 14.54% 0.48x
MASI
Masimo
40.75% 1.411 7.21% 0.87x
MCK
McKesson
157.93% 0.870 6.69% 0.51x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CAH
Cardinal Health
$2.1B $656M 46.27% -- 1.35% $2.8B
BIO
Bio-Rad Laboratories
$306M $23.7M -25.43% -29.59% 16.3% $95.5M
BSX
Boston Scientific
$3.2B $937M 6.35% 9.57% 19.02% $277M
COR
Cencora
$3.1B $1.2B 24.2% 183.42% 1.41% $3.2B
MASI
Masimo
$234M $80.7M -24.62% -39.91% 20.75% $27M
MCK
McKesson
$3.6B $1.7B 79.77% -- 1.72% $7.5B

Cardinal Health vs. Competitors

  • Which has Higher Returns CAH or BIO?

    Bio-Rad Laboratories has a net margin of 0.92% compared to Cardinal Health's net margin of 10.93%. Cardinal Health's return on equity of -- beat Bio-Rad Laboratories's return on equity of -29.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    CAH
    Cardinal Health
    3.87% $2.10 $5.8B
    BIO
    Bio-Rad Laboratories
    52.27% $2.29 $7.9B
  • What do Analysts Say About CAH or BIO?

    Cardinal Health has a consensus price target of $155.47, signalling upside risk potential of 4.76%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $318.67 which suggests that it could grow by 34.42%. Given that Bio-Rad Laboratories has higher upside potential than Cardinal Health, analysts believe Bio-Rad Laboratories is more attractive than Cardinal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    CAH
    Cardinal Health
    9 5 0
    BIO
    Bio-Rad Laboratories
    2 2 0
  • Is CAH or BIO More Risky?

    Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 0.999, suggesting its less volatile than the S&P 500 by 0.087999999999999%.

  • Which is a Better Dividend Stock CAH or BIO?

    Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.36%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CAH or BIO?

    Cardinal Health quarterly revenues are $54.9B, which are larger than Bio-Rad Laboratories quarterly revenues of $585.4M. Cardinal Health's net income of $506M is higher than Bio-Rad Laboratories's net income of $64M. Notably, Cardinal Health's price-to-earnings ratio is 23.15x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.16x versus 2.62x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CAH
    Cardinal Health
    0.16x 23.15x $54.9B $506M
    BIO
    Bio-Rad Laboratories
    2.62x -- $585.4M $64M
  • Which has Higher Returns CAH or BSX?

    Boston Scientific has a net margin of 0.92% compared to Cardinal Health's net margin of 14.45%. Cardinal Health's return on equity of -- beat Boston Scientific's return on equity of 9.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    CAH
    Cardinal Health
    3.87% $2.10 $5.8B
    BSX
    Boston Scientific
    68.84% $0.45 $33.6B
  • What do Analysts Say About CAH or BSX?

    Cardinal Health has a consensus price target of $155.47, signalling upside risk potential of 4.76%. On the other hand Boston Scientific has an analysts' consensus of $116.20 which suggests that it could grow by 12.87%. Given that Boston Scientific has higher upside potential than Cardinal Health, analysts believe Boston Scientific is more attractive than Cardinal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    CAH
    Cardinal Health
    9 5 0
    BSX
    Boston Scientific
    23 4 0
  • Is CAH or BSX More Risky?

    Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

  • Which is a Better Dividend Stock CAH or BSX?

    Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.36%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CAH or BSX?

    Cardinal Health quarterly revenues are $54.9B, which are larger than Boston Scientific quarterly revenues of $4.7B. Cardinal Health's net income of $506M is lower than Boston Scientific's net income of $674M. Notably, Cardinal Health's price-to-earnings ratio is 23.15x while Boston Scientific's PE ratio is 75.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.16x versus 8.73x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CAH
    Cardinal Health
    0.16x 23.15x $54.9B $506M
    BSX
    Boston Scientific
    8.73x 75.15x $4.7B $674M
  • Which has Higher Returns CAH or COR?

    Cencora has a net margin of 0.92% compared to Cardinal Health's net margin of 0.95%. Cardinal Health's return on equity of -- beat Cencora's return on equity of 183.42%.

    Company Gross Margin Earnings Per Share Invested Capital
    CAH
    Cardinal Health
    3.87% $2.10 $5.8B
    COR
    Cencora
    4.06% $3.68 $9B
  • What do Analysts Say About CAH or COR?

    Cardinal Health has a consensus price target of $155.47, signalling upside risk potential of 4.76%. On the other hand Cencora has an analysts' consensus of $317.09 which suggests that it could grow by 13.59%. Given that Cencora has higher upside potential than Cardinal Health, analysts believe Cencora is more attractive than Cardinal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    CAH
    Cardinal Health
    9 5 0
    COR
    Cencora
    9 6 0
  • Is CAH or COR More Risky?

    Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Cencora has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.596%.

  • Which is a Better Dividend Stock CAH or COR?

    Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.36%. Cencora offers a yield of 0.76% to investors and pays a quarterly dividend of $0.55 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Cencora pays out 27.58% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CAH or COR?

    Cardinal Health quarterly revenues are $54.9B, which are smaller than Cencora quarterly revenues of $75.5B. Cardinal Health's net income of $506M is lower than Cencora's net income of $717.9M. Notably, Cardinal Health's price-to-earnings ratio is 23.15x while Cencora's PE ratio is 32.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.16x versus 0.18x for Cencora. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CAH
    Cardinal Health
    0.16x 23.15x $54.9B $506M
    COR
    Cencora
    0.18x 32.38x $75.5B $717.9M
  • Which has Higher Returns CAH or MASI?

    Masimo has a net margin of 0.92% compared to Cardinal Health's net margin of -45.89%. Cardinal Health's return on equity of -- beat Masimo's return on equity of -39.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    CAH
    Cardinal Health
    3.87% $2.10 $5.8B
    MASI
    Masimo
    62.9% -$3.17 $1.6B
  • What do Analysts Say About CAH or MASI?

    Cardinal Health has a consensus price target of $155.47, signalling upside risk potential of 4.76%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 18.89%. Given that Masimo has higher upside potential than Cardinal Health, analysts believe Masimo is more attractive than Cardinal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    CAH
    Cardinal Health
    9 5 0
    MASI
    Masimo
    4 3 0
  • Is CAH or MASI More Risky?

    Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

  • Which is a Better Dividend Stock CAH or MASI?

    Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.36%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CAH or MASI?

    Cardinal Health quarterly revenues are $54.9B, which are larger than Masimo quarterly revenues of $372M. Cardinal Health's net income of $506M is higher than Masimo's net income of -$170.7M. Notably, Cardinal Health's price-to-earnings ratio is 23.15x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.16x versus 4.21x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CAH
    Cardinal Health
    0.16x 23.15x $54.9B $506M
    MASI
    Masimo
    4.21x 116.80x $372M -$170.7M
  • Which has Higher Returns CAH or MCK?

    McKesson has a net margin of 0.92% compared to Cardinal Health's net margin of 1.39%. Cardinal Health's return on equity of -- beat McKesson's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CAH
    Cardinal Health
    3.87% $2.10 $5.8B
    MCK
    McKesson
    4.01% $10.01 $4B
  • What do Analysts Say About CAH or MCK?

    Cardinal Health has a consensus price target of $155.47, signalling upside risk potential of 4.76%. On the other hand McKesson has an analysts' consensus of $744.58 which suggests that it could grow by 9.13%. Given that McKesson has higher upside potential than Cardinal Health, analysts believe McKesson is more attractive than Cardinal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    CAH
    Cardinal Health
    9 5 0
    MCK
    McKesson
    10 3 0
  • Is CAH or MCK More Risky?

    Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison McKesson has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.469%.

  • Which is a Better Dividend Stock CAH or MCK?

    Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.36%. McKesson offers a yield of 0.4% to investors and pays a quarterly dividend of $0.71 per share. Cardinal Health pays 58.57% of its earnings as a dividend. McKesson pays out 10.47% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CAH or MCK?

    Cardinal Health quarterly revenues are $54.9B, which are smaller than McKesson quarterly revenues of $90.8B. Cardinal Health's net income of $506M is lower than McKesson's net income of $1.3B. Notably, Cardinal Health's price-to-earnings ratio is 23.15x while McKesson's PE ratio is 26.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.16x versus 0.24x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CAH
    Cardinal Health
    0.16x 23.15x $54.9B $506M
    MCK
    McKesson
    0.24x 26.41x $90.8B $1.3B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Uber Stock 5X?
Will Uber Stock 5X?

Uber (NYSE:UBER) has generated extremely strong returns for its investors…

How High Will Bloom Energy Stock Go?
How High Will Bloom Energy Stock Go?

Bloom Energy (NYSE:BE) has seen its shares surge by more…

Is Acuity a Good Stock to Buy Now?
Is Acuity a Good Stock to Buy Now?

Acuity Brands (NYSE:AYI) is an industrial company specializing in lighting.…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 38x

Buy
74
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
49
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
71
NUTX alert for May 15

Nutex Health [NUTX] is up 9.76% over the past day.

Buy
81
EXEL alert for May 15

Exelixis [EXEL] is up 3.67% over the past day.

Sell
29
GLBE alert for May 15

Global E Online [GLBE] is down 3.44% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock